0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Plasma-based Hyperimmune Preparation Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-12T14076
Home | Market Reports | Health| Medical Facilities & Services| Medical Procedures
Global Human Plasma based Hyperimmune Preparation Market Research Report 2023
BUY CHAPTERS

Global Human Plasma-based Hyperimmune Preparation Market Research Report 2025

Code: QYRE-Auto-12T14076
Report
May 2025
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Human Plasma-based Hyperimmune Preparation Market Size

The global market for Human Plasma-based Hyperimmune Preparation was valued at US$ 2095 million in the year 2024 and is projected to reach a revised size of US$ 3163 million by 2031, growing at a CAGR of 6.2% during the forecast period.

Human Plasma-based Hyperimmune Preparation Market

Human Plasma-based Hyperimmune Preparation Market

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Plasma-based Hyperimmune Preparation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Plasma-based Hyperimmune Preparation.
The Human Plasma-based Hyperimmune Preparation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Plasma-based Hyperimmune Preparation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Plasma-based Hyperimmune Preparation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Human Plasma-based Hyperimmune Preparation Market Report

Report Metric Details
Report Name Human Plasma-based Hyperimmune Preparation Market
Accounted market size in year US$ 2095 million
Forecasted market size in 2031 US$ 3163 million
CAGR 6.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Government Institution
  • Private Sector
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG, Hualan Bio, Shanghai RAAS, Sichuan Yuanda Shuyang, ADMA Biologics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Human Plasma-based Hyperimmune Preparation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Human Plasma-based Hyperimmune Preparation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Human Plasma-based Hyperimmune Preparation Market growing?

Ans: The Human Plasma-based Hyperimmune Preparation Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the Human Plasma-based Hyperimmune Preparation Market size in 2031?

Ans: The Human Plasma-based Hyperimmune Preparation Market size in 2031 will be US$ 3163 million.

Who are the main players in the Human Plasma-based Hyperimmune Preparation Market report?

Ans: The main players in the Human Plasma-based Hyperimmune Preparation Market are CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG, Hualan Bio, Shanghai RAAS, Sichuan Yuanda Shuyang, ADMA Biologics

What are the Application segmentation covered in the Human Plasma-based Hyperimmune Preparation Market report?

Ans: The Applications covered in the Human Plasma-based Hyperimmune Preparation Market report are Government Institution, Private Sector, Others

What are the Type segmentation covered in the Human Plasma-based Hyperimmune Preparation Market report?

Ans: The Types covered in the Human Plasma-based Hyperimmune Preparation Market report are Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins, Rho(D) Immunoglobulins, Other

Recommended Reports

Plasma-derived Treatments

Immunoglobulins Market

Blood Plasma Testing

1 Human Plasma-based Hyperimmune Preparation Market Overview
1.1 Product Definition
1.2 Human Plasma-based Hyperimmune Preparation by Type
1.2.1 Global Human Plasma-based Hyperimmune Preparation Market Value Comparison by Type (2024 VS 2031)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Other
1.3 Human Plasma-based Hyperimmune Preparation by Application
1.3.1 Global Human Plasma-based Hyperimmune Preparation Market Value by Application (2024 VS 2031)
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Others
1.4 Global Human Plasma-based Hyperimmune Preparation Market Size Estimates and Forecasts
1.4.1 Global Human Plasma-based Hyperimmune Preparation Revenue 2020-2031
1.4.2 Global Human Plasma-based Hyperimmune Preparation Sales 2020-2031
1.4.3 Global Human Plasma-based Hyperimmune Preparation Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Human Plasma-based Hyperimmune Preparation Market Competition by Manufacturers
2.1 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Manufacturers (2020-2025)
2.2 Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Human Plasma-based Hyperimmune Preparation Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Plasma-based Hyperimmune Preparation, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Plasma-based Hyperimmune Preparation, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Plasma-based Hyperimmune Preparation, Product Type & Application
2.7 Global Key Manufacturers of Human Plasma-based Hyperimmune Preparation, Date of Enter into This Industry
2.8 Global Human Plasma-based Hyperimmune Preparation Market Competitive Situation and Trends
2.8.1 Global Human Plasma-based Hyperimmune Preparation Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Plasma-based Hyperimmune Preparation Players Market Share by Revenue
2.8.3 Global Human Plasma-based Hyperimmune Preparation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Plasma-based Hyperimmune Preparation Market Scenario by Region
3.1 Global Human Plasma-based Hyperimmune Preparation Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2020-2031
3.2.1 Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2020-2025
3.2.2 Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2026-2031
3.3 Global Human Plasma-based Hyperimmune Preparation Revenue by Region: 2020-2031
3.3.1 Global Human Plasma-based Hyperimmune Preparation Revenue by Region: 2020-2025
3.3.2 Global Human Plasma-based Hyperimmune Preparation Revenue by Region: 2026-2031
3.4 North America Human Plasma-based Hyperimmune Preparation Market Facts & Figures by Country
3.4.1 North America Human Plasma-based Hyperimmune Preparation Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2031)
3.4.3 North America Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Plasma-based Hyperimmune Preparation Market Facts & Figures by Country
3.5.1 Europe Human Plasma-based Hyperimmune Preparation Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2031)
3.5.3 Europe Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Plasma-based Hyperimmune Preparation Market Facts & Figures by Region
3.6.1 Asia Pacific Human Plasma-based Hyperimmune Preparation Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Plasma-based Hyperimmune Preparation Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Plasma-based Hyperimmune Preparation Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Human Plasma-based Hyperimmune Preparation Market Facts & Figures by Country
3.7.1 Latin America Human Plasma-based Hyperimmune Preparation Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2031)
3.7.3 Latin America Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Plasma-based Hyperimmune Preparation Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Plasma-based Hyperimmune Preparation Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Plasma-based Hyperimmune Preparation Sales by Type (2020-2031)
4.1.1 Global Human Plasma-based Hyperimmune Preparation Sales by Type (2020-2025)
4.1.2 Global Human Plasma-based Hyperimmune Preparation Sales by Type (2026-2031)
4.1.3 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2020-2031)
4.2 Global Human Plasma-based Hyperimmune Preparation Revenue by Type (2020-2031)
4.2.1 Global Human Plasma-based Hyperimmune Preparation Revenue by Type (2020-2025)
4.2.2 Global Human Plasma-based Hyperimmune Preparation Revenue by Type (2026-2031)
4.2.3 Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2020-2031)
4.3 Global Human Plasma-based Hyperimmune Preparation Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Plasma-based Hyperimmune Preparation Sales by Application (2020-2031)
5.1.1 Global Human Plasma-based Hyperimmune Preparation Sales by Application (2020-2025)
5.1.2 Global Human Plasma-based Hyperimmune Preparation Sales by Application (2026-2031)
5.1.3 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2020-2031)
5.2 Global Human Plasma-based Hyperimmune Preparation Revenue by Application (2020-2031)
5.2.1 Global Human Plasma-based Hyperimmune Preparation Revenue by Application (2020-2025)
5.2.2 Global Human Plasma-based Hyperimmune Preparation Revenue by Application (2026-2031)
5.2.3 Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application (2020-2031)
5.3 Global Human Plasma-based Hyperimmune Preparation Price by Application (2020-2031)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Company Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.1.4 CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Company Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Grifols Human Plasma-based Hyperimmune Preparation Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Company Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Biotest Human Plasma-based Hyperimmune Preparation Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Company Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Company Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.5.4 CBPO Human Plasma-based Hyperimmune Preparation Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Company Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.7.1 Kamada Company Information
6.7.2 Kamada Description and Business Overview
6.7.3 Kamada Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Kamada Human Plasma-based Hyperimmune Preparation Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Company Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.8.4 CNBG Human Plasma-based Hyperimmune Preparation Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Company Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Company Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Company Information
6.11.2 Sichuan Yuanda Shuyang Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Company Information
6.12.2 ADMA Biologics Description and Business Overview
6.12.3 ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales, Revenue and Gross Margin (2020-2025)
6.12.4 ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Plasma-based Hyperimmune Preparation Industry Chain Analysis
7.2 Human Plasma-based Hyperimmune Preparation Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Plasma-based Hyperimmune Preparation Production Mode & Process Analysis
7.4 Human Plasma-based Hyperimmune Preparation Sales and Marketing
7.4.1 Human Plasma-based Hyperimmune Preparation Sales Channels
7.4.2 Human Plasma-based Hyperimmune Preparation Distributors
7.5 Human Plasma-based Hyperimmune Preparation Customer Analysis
8 Human Plasma-based Hyperimmune Preparation Market Dynamics
8.1 Human Plasma-based Hyperimmune Preparation Industry Trends
8.2 Human Plasma-based Hyperimmune Preparation Market Drivers
8.3 Human Plasma-based Hyperimmune Preparation Market Challenges
8.4 Human Plasma-based Hyperimmune Preparation Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Human Plasma-based Hyperimmune Preparation Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Human Plasma-based Hyperimmune Preparation Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Human Plasma-based Hyperimmune Preparation Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Human Plasma-based Hyperimmune Preparation Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Human Plasma-based Hyperimmune Preparation Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Human Plasma-based Hyperimmune Preparation Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Human Plasma-based Hyperimmune Preparation Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Human Plasma-based Hyperimmune Preparation, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Human Plasma-based Hyperimmune Preparation, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Human Plasma-based Hyperimmune Preparation, Product Type & Application
 Table 12. Global Key Manufacturers of Human Plasma-based Hyperimmune Preparation, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Plasma-based Hyperimmune Preparation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Plasma-based Hyperimmune Preparation as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Plasma-based Hyperimmune Preparation Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Human Plasma-based Hyperimmune Preparation Sales by Region (2020-2025) & (K Units)
 Table 18. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2020-2025)
 Table 19. Global Human Plasma-based Hyperimmune Preparation Sales by Region (2026-2031) & (K Units)
 Table 20. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2026-2031)
 Table 21. Global Human Plasma-based Hyperimmune Preparation Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Region (2020-2025)
 Table 23. Global Human Plasma-based Hyperimmune Preparation Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Region (2026-2031)
 Table 25. North America Human Plasma-based Hyperimmune Preparation Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2025) & (K Units)
 Table 27. North America Human Plasma-based Hyperimmune Preparation Sales by Country (2026-2031) & (K Units)
 Table 28. North America Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Human Plasma-based Hyperimmune Preparation Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Human Plasma-based Hyperimmune Preparation Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Human Plasma-based Hyperimmune Preparation Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Human Plasma-based Hyperimmune Preparation Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Human Plasma-based Hyperimmune Preparation Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Human Plasma-based Hyperimmune Preparation Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Human Plasma-based Hyperimmune Preparation Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Human Plasma-based Hyperimmune Preparation Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Human Plasma-based Hyperimmune Preparation Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Human Plasma-based Hyperimmune Preparation Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Human Plasma-based Hyperimmune Preparation Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Human Plasma-based Hyperimmune Preparation Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Human Plasma-based Hyperimmune Preparation Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Human Plasma-based Hyperimmune Preparation Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Human Plasma-based Hyperimmune Preparation Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Human Plasma-based Hyperimmune Preparation Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Human Plasma-based Hyperimmune Preparation Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Human Plasma-based Hyperimmune Preparation Sales (K Units) by Type (2020-2025)
 Table 51. Global Human Plasma-based Hyperimmune Preparation Sales (K Units) by Type (2026-2031)
 Table 52. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2020-2025)
 Table 53. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2026-2031)
 Table 54. Global Human Plasma-based Hyperimmune Preparation Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Human Plasma-based Hyperimmune Preparation Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2020-2025)
 Table 57. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2026-2031)
 Table 58. Global Human Plasma-based Hyperimmune Preparation Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Human Plasma-based Hyperimmune Preparation Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Human Plasma-based Hyperimmune Preparation Sales (K Units) by Application (2020-2025)
 Table 61. Global Human Plasma-based Hyperimmune Preparation Sales (K Units) by Application (2026-2031)
 Table 62. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2020-2025)
 Table 63. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2026-2031)
 Table 64. Global Human Plasma-based Hyperimmune Preparation Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Human Plasma-based Hyperimmune Preparation Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application (2020-2025)
 Table 67. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application (2026-2031)
 Table 68. Global Human Plasma-based Hyperimmune Preparation Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Human Plasma-based Hyperimmune Preparation Price (US$/Unit) by Application (2026-2031)
 Table 70. CSL Behring Company Information
 Table 71. CSL Behring Description and Business Overview
 Table 72. CSL Behring Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. CSL Behring Human Plasma-based Hyperimmune Preparation Product
 Table 74. CSL Behring Recent Developments/Updates
 Table 75. Grifols Company Information
 Table 76. Grifols Description and Business Overview
 Table 77. Grifols Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Grifols Human Plasma-based Hyperimmune Preparation Product
 Table 79. Grifols Recent Developments/Updates
 Table 80. Biotest Company Information
 Table 81. Biotest Description and Business Overview
 Table 82. Biotest Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Biotest Human Plasma-based Hyperimmune Preparation Product
 Table 84. Biotest Recent Developments/Updates
 Table 85. Kedrion Company Information
 Table 86. Kedrion Description and Business Overview
 Table 87. Kedrion Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Kedrion Human Plasma-based Hyperimmune Preparation Product
 Table 89. Kedrion Recent Developments/Updates
 Table 90. CBPO Company Information
 Table 91. CBPO Description and Business Overview
 Table 92. CBPO Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. CBPO Human Plasma-based Hyperimmune Preparation Product
 Table 94. CBPO Recent Developments/Updates
 Table 95. Emergent (Cangene) Company Information
 Table 96. Emergent (Cangene) Description and Business Overview
 Table 97. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product
 Table 99. Emergent (Cangene) Recent Developments/Updates
 Table 100. Kamada Company Information
 Table 101. Kamada Description and Business Overview
 Table 102. Kamada Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Kamada Human Plasma-based Hyperimmune Preparation Product
 Table 104. Kamada Recent Developments/Updates
 Table 105. CNBG Company Information
 Table 106. CNBG Description and Business Overview
 Table 107. CNBG Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. CNBG Human Plasma-based Hyperimmune Preparation Product
 Table 109. CNBG Recent Developments/Updates
 Table 110. Hualan Bio Company Information
 Table 111. Hualan Bio Description and Business Overview
 Table 112. Hualan Bio Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Hualan Bio Human Plasma-based Hyperimmune Preparation Product
 Table 114. Hualan Bio Recent Developments/Updates
 Table 115. Shanghai RAAS Company Information
 Table 116. Shanghai RAAS Description and Business Overview
 Table 117. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product
 Table 119. Shanghai RAAS Recent Developments/Updates
 Table 120. Sichuan Yuanda Shuyang Company Information
 Table 121. Sichuan Yuanda Shuyang Description and Business Overview
 Table 122. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product
 Table 124. Sichuan Yuanda Shuyang Recent Developments/Updates
 Table 125. ADMA Biologics Company Information
 Table 126. ADMA Biologics Description and Business Overview
 Table 127. ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. ADMA Biologics Human Plasma-based Hyperimmune Preparation Product
 Table 129. ADMA Biologics Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Human Plasma-based Hyperimmune Preparation Distributors List
 Table 133. Human Plasma-based Hyperimmune Preparation Customers List
 Table 134. Human Plasma-based Hyperimmune Preparation Market Trends
 Table 135. Human Plasma-based Hyperimmune Preparation Market Drivers
 Table 136. Human Plasma-based Hyperimmune Preparation Market Challenges
 Table 137. Human Plasma-based Hyperimmune Preparation Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Plasma-based Hyperimmune Preparation
 Figure 2. Global Human Plasma-based Hyperimmune Preparation Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Human Plasma-based Hyperimmune Preparation Market Share by Type: 2024 & 2031
 Figure 4. Hepatitis B Immunoglobulins Product Picture
 Figure 5. Rabies Immunoglobulins Product Picture
 Figure 6. Tetanus Immunoglobulins Product Picture
 Figure 7. Rho(D) Immunoglobulins Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Human Plasma-based Hyperimmune Preparation Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Human Plasma-based Hyperimmune Preparation Market Share by Application: 2024 & 2031
 Figure 11. Government Institution
 Figure 12. Private Sector
 Figure 13. Others
 Figure 14. Global Human Plasma-based Hyperimmune Preparation Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Human Plasma-based Hyperimmune Preparation Market Size (2020-2031) & (US$ Million)
 Figure 16. Global Human Plasma-based Hyperimmune Preparation Sales (2020-2031) & (K Units)
 Figure 17. Global Human Plasma-based Hyperimmune Preparation Average Price (US$/Unit) & (2020-2031)
 Figure 18. Human Plasma-based Hyperimmune Preparation Report Years Considered
 Figure 19. Human Plasma-based Hyperimmune Preparation Sales Share by Manufacturers in 2024
 Figure 20. Global Human Plasma-based Hyperimmune Preparation Revenue Share by Manufacturers in 2024
 Figure 21. Global 5 and 10 Largest Human Plasma-based Hyperimmune Preparation Players: Market Share by Revenue in Human Plasma-based Hyperimmune Preparation in 2024
 Figure 22. Human Plasma-based Hyperimmune Preparation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 23. Global Human Plasma-based Hyperimmune Preparation Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 24. North America Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2020-2031)
 Figure 25. North America Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2020-2031)
 Figure 26. United States Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Canada Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2020-2031)
 Figure 29. Europe Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2020-2031)
 Figure 30. Germany Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. France Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. U.K. Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Italy Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Russia Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Asia Pacific Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2020-2031)
 Figure 36. Asia Pacific Human Plasma-based Hyperimmune Preparation Revenue Market Share by Region (2020-2031)
 Figure 37. China Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Japan Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. South Korea Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. India Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Australia Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. China Taiwan Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Southeast Asia Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Human Plasma-based Hyperimmune Preparation Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Human Plasma-based Hyperimmune Preparation by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Human Plasma-based Hyperimmune Preparation by Type (2020-2031)
 Figure 56. Global Human Plasma-based Hyperimmune Preparation Price (US$/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Human Plasma-based Hyperimmune Preparation by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Human Plasma-based Hyperimmune Preparation by Application (2020-2031)
 Figure 59. Global Human Plasma-based Hyperimmune Preparation Price (US$/Unit) by Application (2020-2031)
 Figure 60. Human Plasma-based Hyperimmune Preparation Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

RELATED REPORTS

Global Assisted Spine Surgery Robot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30V16581
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global ENT Surgery Navigation Software Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-11O6178
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Robotics in Laparoscopic Surgery Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-7R6277
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Bone Allografts Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9I8785
Tue Sep 09 00:00:00 UTC 2025

Add to Cart